Bristol-Myers Squibb Co. (BMY) News
Filter BMY News Items
BMY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BMY News Highlights
- For BMY, its 30 day story count is now at 22.
- Over the past 19 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about BMY are DRUG, ABBV and ACT.
Latest BMY News From Around the Web
Below are the latest news stories about BRISTOL MYERS SQUIBB CO that investors may wish to consider to help them evaluate BMY as an investment opportunity.
UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal terminationBeiGene and Swiss drugmaker Novartis have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months. BeiGene will regain full global rights to the drug, tislelizumab, or Tevimbra, with no royalty payments due to Novartis, which will continue to manufacture it. Novartis had paid $650 million to gain those rights in 2021. |
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should KnowBristol Myers Squibb (BMY) closed at $58.58 in the latest trading session, marking a -0.76% move from the prior day. |
FDA approves GSK's unique myelofibrosis treatment OjjaaraThe US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review. |
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substanceSamsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. |
The 3 Most Undervalued Pharma Stocks to Buy in September 2023Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now. |
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study UpdatesPipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector. |
Bristol Myers plans to double experimental treatments to expand research pipelineThe drugmaker, which currently has six candidates in trials, will advance six more in its research pipeline - including three cell therapies that target immune system disorders and different types of cancer. The New York-based company has been pressured by declining demand for two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, which face generic competition. Bristol and partner Pfizer's blood thinner Eliquis was also on the list of 10 drugs that will be subject to the first-ever price negotiations by the U.S. Medicare health program. |
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D DayPRINCETON, N.J., September 14, 2023--Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day |
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.Roz Brewer stepped down from leading Walgreens, and the next CEO is a tough choice. |
2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics. |